(IART) Integra LifeSciences - Overview
Stock: Neurosurgical, Otologic, Wound, Instrument, Dural
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 72.4% |
| Relative Tail Risk | -14.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.07 |
| Alpha | -77.98 |
| Character TTM | |
|---|---|
| Beta | 1.358 |
| Beta Downside | 1.294 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.72% |
| CAGR/Max DD | -0.53 |
Description: IART Integra LifeSciences January 18, 2026
Integra LifeSciences Holdings Corp. (NASDAQ:IART) designs, manufactures, and markets a broad portfolio of medical devices spanning neurosurgery, neuro-critical care, otolaryngology, and wound-care. The business is organized into two primary segments: Codman Specialty Surgical, which supplies neurosurgical and neuro-critical care tools (e.g., tissue ablation, dural repair, intracranial monitoring, cranial stabilization, and surgical headlamps), and Tissue Technologies, which focuses on wound-healing, plastic-reconstructive, and general-surgery products such as skin grafts, bone grafts, and nerve/tendon repair kits. Distribution is handled through direct sales forces and third-party channels to hospitals, integrated health systems, group purchasing organizations, and specialty clinics across the U.S., Europe, Asia-Pacific, and other international markets.
As of FY 2024, Integra reported revenue of approximately $1.9 billion, reflecting a 7 % year-over-year increase driven largely by higher adoption of its Codman neuro-critical care platforms and expanding wound-care product line in the diabetic foot-ulcer segment. The company’s gross margin stabilized near 55 %, while R&D spending averaged 9 % of revenue, underscoring a continued focus on product innovation in minimally invasive neurosurgical tools. Key macro drivers include an aging global population increasing demand for neurosurgical interventions, rising prevalence of chronic wounds linked to diabetes, and sustained hospital capital-expenditure cycles despite macro-economic headwinds.
If you’re looking for a deeper, data-driven analysis of IART’s valuation and risk profile, a quick look at ValueRay’s research hub could be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: -495.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -1.33 > 1.0 |
| NWC/Revenue: 47.45% < 20% (prev 11.95%; Δ 35.50% < -1%) |
| CFO/TA 0.02 > 3% & CFO 89.3m > Net Income -495.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (76.8m) vs 12m ago 0.40% < -2% |
| Gross Margin: 53.50% > 18% (prev 0.55%; Δ 5295 % > 0.5%) |
| Asset Turnover: 42.61% > 50% (prev 38.49%; Δ 4.12% > 0%) |
| Interest Coverage Ratio: -5.59 > 6 (EBITDA TTM -313.1m / Interest Expense TTM 83.0m) |
Altman Z'' 1.13
| A: 0.21 (Total Current Assets 1.14b - Total Current Liabilities 364.1m) / Total Assets 3.65b |
| B: 0.12 (Retained Earnings 425.1m / Total Assets 3.65b) |
| C: -0.12 (EBIT TTM -463.6m / Avg Total Assets 3.86b) |
| D: 0.15 (Book Value of Equity 394.1m / Total Liabilities 2.61b) |
| Altman-Z'' Score: 1.13 = BB |
Beneish M -3.19
| DSRI: 1.01 (Receivables 262.2m/248.3m, Revenue 1.64b/1.56b) |
| GMI: 1.03 (GM 53.50% / 54.92%) |
| AQI: 0.88 (AQ_t 0.53 / AQ_t-1 0.60) |
| SGI: 1.05 (Revenue 1.64b / 1.56b) |
| TATA: -0.16 (NI -495.3m - CFO 89.3m) / TA 3.65b) |
| Beneish M-Score: -3.19 (Cap -4..+1) = AA |
What is the price of IART shares?
Over the past week, the price has changed by -2.06%, over one month by -19.51%, over three months by -10.26% and over the past year by -57.27%.
Is IART a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 5
- Sell: 2
- StrongSell: 2
What are the forecasts/targets for the IART price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.5 | 41.8% |
| Analysts Target Price | 15.5 | 41.8% |
| ValueRay Target Price | 6.5 | -40.4% |
IART Fundamental Data Overview February 03, 2026
P/S = 0.5283
P/B = 0.8325
P/EG = 0.7128
Revenue TTM = 1.64b USD
EBIT TTM = -463.6m USD
EBITDA TTM = -313.1m USD
Long Term Debt = 1.79b USD (from longTermDebt, last quarter)
Short Term Debt = 52.6m USD (from shortTermDebt, last quarter)
Debt = 2.01b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.77b USD (from netDebt column, last quarter)
Enterprise Value = 2.61b USD (867.9m + Debt 2.01b - CCE 267.9m)
Interest Coverage Ratio = -5.59 (Ebit TTM -463.6m / Interest Expense TTM 83.0m)
EV/FCF = -180.1x (Enterprise Value 2.61b / FCF TTM -14.5m)
FCF Yield = -0.56% (FCF TTM -14.5m / Enterprise Value 2.61b)
FCF Margin = -0.88% (FCF TTM -14.5m / Revenue TTM 1.64b)
Net Margin = -30.15% (Net Income TTM -495.3m / Revenue TTM 1.64b)
Gross Margin = 53.50% ((Revenue TTM 1.64b - Cost of Revenue TTM 764.0m) / Revenue TTM)
Gross Margin QoQ = 56.24% (prev 50.37%)
Tobins Q-Ratio = 0.71 (Enterprise Value 2.61b / Total Assets 3.65b)
Interest Expense / Debt = 1.13% (Interest Expense 22.7m / Debt 2.01b)
Taxrate = 21.0% (US default 21%)
NOPAT = -366.3m (EBIT -463.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.14 (Total Current Assets 1.14b / Total Current Liabilities 364.1m)
Debt / Equity = 1.93 (Debt 2.01b / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = -5.67 (negative EBITDA) (Net Debt 1.77b / EBITDA -313.1m)
Debt / FCF = -122.6 (out of range, set to none) (Net Debt 1.77b / FCF TTM -14.5m)
Total Stockholder Equity = 1.29b (last 4 quarters mean from totalStockholderEquity)
RoA = -12.85% (Net Income -495.3m / Total Assets 3.65b)
RoE = -38.51% (Net Income TTM -495.3m / Total Stockholder Equity 1.29b)
RoCE = -15.06% (EBIT -463.6m / Capital Employed (Equity 1.29b + L.T.Debt 1.79b))
RoIC = -11.75% (negative operating profit) (NOPAT -366.3m / Invested Capital 3.12b)
WACC = 3.92% (E(867.9m)/V(2.87b) * Re(10.92%) + D(2.01b)/V(2.87b) * Rd(1.13%) * (1-Tc(0.21)))
Discount Rate = 10.92% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.01%
Fair Price DCF = unknown (Cash Flow -14.5m)
EPS Correlation: -62.03 | EPS CAGR: -24.26% | SUE: -2.79 | # QB: 0
Revenue Correlation: 30.63 | Revenue CAGR: -0.23% | SUE: -1.53 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.48 | Chg30d=-0.005 | Revisions Net=+2 | Analysts=8
EPS next Year (2026-12-31): EPS=2.35 | Chg30d=-0.007 | Revisions Net=+0 | Growth EPS=+6.9% | Growth Revenue=+2.8%